Status:
UNKNOWN
Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection
Lead Sponsor:
Sherief Abd-Elsalam
Conditions:
Bleeding Esophageal Varices
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection
Detailed Description
Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices
Eligibility Criteria
Inclusion
- cirrhotic patients presented with actively bleeding
Exclusion
- other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT03388125
Start Date
January 1 2016
End Date
December 1 2022
Last Update
April 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sherief Abd-Elsalam
Tanta, Egypt